Iloprost and tissue-type plasminogen activator differentially affect platelet aggregation in platelet-rich plasma and in whole blood.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Thrombosis Research

• Publication date

  1990-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0049-3848(90)90216-YPMID 1707560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.

  1990cited by this paper
• Generation of nitric oxide by human neutrophils.

  1989cited by this paper
• Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor.

  1989cited by this paper
• N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor.

  1989cited by this paper
• Synergistic Disaggregation of Platelets by Tissue-Type Plasminogen Activator, Prostaglandin El9 and Nitroglycerin

  1989cited by this paper
• Tissue-type plasminogen activator inhibits aggregation of platelets in vitro.

  1988cited by this paper
• Critical evaluation of platelet aggregation in whole human blood.

  1986cited by this paper
• Plasmin inhibition of platelet function and of arachidonic acid metabolism.

  1985cited by this paper
• Dipyridamole Inhibits Platelet Aggregation in Whole Blood

  1983cited by this paper
• Uptake and metabolism of adenosine by human erythrocyte ghosts.

  1972cited by this paper

• [Pharmacological profiles and clinical effects of oral sustained release beraprost sodium (Careload LA tablets 60 microg, Berasus LA tablets 60 microg)].

  2009cites this paper
• Platelet inhibitory effect of nitroglycerin in platelet-rich plasma: relevance of glutathione-s-transferases in plasma.

  1996cites this paper
• Interactions between endothelial mediators.

  1995cites this paper
• Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.

  1995cites this paper
• Lys- and glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation.

  1994cites this paper
• Biochemical and Molecular Roles of Nutrients Dietary Fish Oil Supplementation Attenuates Myocardial Dysfunction and Injury Caused by Global Ischemia and Reperfusion in Isolated Rat Hearts1'2

  1993cites this paper
• Dietary fish oil supplementation attenuates myocardial dysfunction and injury caused by global ischemia and reperfusion in isolated rat hearts.

  1993cites this paper
• Platelets protect against myocardial dysfunction and injury induced by ischemia and reperfusion in isolated rat hearts.

  1993cites this paper
• Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.

  1993cites this paper
• Interactions Between Nitric Oxide and Prostacyclin

  1993cites this paper
• Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.

  1992cites this paper